GET DAILY SIGNALS$MRNA, $ALNY, $GMAB, $BGNE, $ROIV, $HALO, and $PCVX: Biotech sector stocks that have fallen by over 10% in the past month.
Some biotech sector stocks have experienced more significant declines in the past month compared to the overall market, with drops exceeding 10%. For quick trade insights, you can subscribe to our robots at Swing-Trader-High-Volatility-Stocks-for-Active-Trading-TA-FA.
The group's average market capitalization is $21.3 billion, ranging from $7.9 billion (ROIV) to $37.4 billion (MRNA).
In terms of price performance, the average weekly change was -4.48%, monthly change was -12.29%, and quarterly change was -13.57%. Notably, BGNE had the highest weekly price growth at 2.82%, while GMAB experienced the largest decline at -8.22%.
Regarding trading volume, the group had an average weekly volume growth of 19.56%. Monthly volume growth averaged 22.22%, and quarterly volume growth averaged 48.52%.
In terms of fundamental analysis ratings (scale: 1 to 100, with 1 being the best and 100 being the worst):
- Valuation Rating: 74
- P/E Growth Rating: 76
- Price Growth Rating: 65
- SMR Rating: 77
- Profit Risk Rating: 70
The Seasonality Score is 25 on a scale of -100 to +100.
MRNA's Stochastic Oscillator exited the overbought zone on October 12, 2023, signaling a potential bearish trend with a 90% likelihood of a decline.
- MRNA Current price: $98.30; trading between $175.56 resistance and $69.57 support lines. It experienced a -9% Downtrend in the month of 09/13/23 - 10/13/23, with a -5% weekly fall.
GMAB's MACD Histogram turned negative on October 12, 2023, suggesting a potential stock decline with a 69% probability.
- GMAB Current price: $32.28; below the $33.91 lowest support line. It faced an -11% Downtrend in the month of 09/13/23 - 10/13/23, dropping -8% weekly.
BGNE's RSI Oscillator exited the oversold zone on October 05, 2023, indicating a potential shift from a downtrend to an uptrend with an 82% probability.
- BGNE Current price: $178.79; below the $239.67 lowest resistance line. It experienced an -11% Downtrend in the month of 09/13/23 - 10/13/23, but showed a +3% Uptrend in the week of 10/06/23 - 10/13/23.
ROIV's RSI Oscillator moved out of the overbought zone on September 28, 2023, hinting at a possible shift from an uptrend to a downtrend with a 78% chance of a decline.
- ROIV Current price: $10.08; above the $8.59 highest resistance line. It faced a -10% Downtrend during the month of 09/13/23 - 10/13/23 and declined -7% weekly.
HALO's Momentum Indicator turned negative on September 26, 2023, suggesting a new potential downward trend with a 69% likelihood.
- HALO Current price: $36.55; below the $39.43 lowest support line. It experienced an -11% Downtrend during the month of 09/13/23 - 10/13/23 and fell -2% weekly.
PCVX's Stochastic Oscillator has been in the oversold zone for 1 day, indicating a potential upcoming price bounce.
- PCVX Current price: $46.00; trading between $61.37 resistance and $23.75 support lines. It experienced an -11% Downtrend during the month of 09/13/23 - 10/13/23 and declined -6% weekly.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
HALO in +2.28% Uptrend, advancing for three consecutive days on October 27, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HALO advanced for three days, in 276 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on HALO as a result. In 58 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for HALO just turned positive on October 15, 2026. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in 26 of 35 cases over the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 250 of 322 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
HALO broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HALO's P/B Ratio (102.813) is slightly higher than the industry average of (2.974). P/E Ratio (36.628) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (7.968) is also within normal values, averaging (439.237).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology
Advertisement